Abstract:Genitourinary problems, including neurogenic dysfunction, impotence, prostatism, urinary tract infections, and prostate cancer, are common in the elderly, and most of the symptoms can be alleviated through pharmacological management.Patients with neurogenic dysfunction who present with symptoms such as incontinence and urinary retention can be appropriately managed with bladder and sphincter relaxants or stimulants. Anticholinergic agents in the form of oxybutynin, flavoxate, and propantheline are effective bladder relaxants, and phenoxybenzamine, prazosin, and terazosin are commonly used as sphincter relaxants. Bethanechol chloride is the agent most commonly used to stimulate bladder contraction, but physicians should be careful when prescribing it for elderly patients with cardiovascular problems.Organic and psychogenic causes of impotence usually overlap, and oral agents have limited use in the treatment process. The use of yohimbine has increased recently, but its value and rate of success remains questionable. Testosterone is being used widely to treat impotence, but it is only helpful to patients with hypogonadism and should be used with discretion in the elderly, who have a high incidence of prostate cancer. Vasoactive intracavernous pharmacotherapy, on the other hand, is a recently discovered alternative to testosterone with promising results.Although the treatment of choice for benign prostatic hypertrophy is surgery, there have been important pharmacological advances in treating this disorder. α-Adrenergic antagonists and antiandrogenic agents have been found to relieve the symptoms of prostatic enlargement.The use of chemotherapeutic and antibiotic agents to treat and suppress acute and chronic urinary tract infections is reviewed; these are second only to pulmonary infections as the most frequent cause of febrile episodes in patients over the age of 65. Lower urinary tract infections can be treated with almost any antibacterial agent. Upper urinary tract infections require full genitourinary evaluation and appropriate antibiotics should be used according to the urine culture sensitivity studies.With the advent of new hormonal agents, more choices are now available for the management of prostate cancer, which is the second most common malignancy in men. Diethylstilbestrol (stilboestrol), an oral estrogen, remains a commonly used agent to achieve castrate levels of androgens in advanced prostatic carcinoma. Agonist analogues, such as goserelin and leuprorelin, of gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH); or gonadorelin] achieve the same results as diethylstilbestrol but without the cardiovascular side effects. Antiandrogens are also being used in combination with GnRH agonists to produce complete androgen blockage, with mixed results.

The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy.

Immunological studies on the gastric diseases

Update on Overactive Bladder Therapeutic Options

Special Purpose Ammonia Frequency Standard a Feasibility Study

Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review

Lipothymoadenoma of the parathyroid.

Emerging therapies for overactive bladder: preclinical, phase I and phase II studies

No. 283-Treatments for Overactive Bladder: Focus on Pharmacotherapy

Recent advances in managing overactive bladder

High order methods for elliptic and time dependent reaction-diffusion singularly perturbed problems

Shifting the treatment paradigm in idiopathic overactive bladder

[Methods for identification of cancer genes].

[A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer].

Kinetic studies of Thermobifida fusca Cel9A active site mutant enzymes.

The Non-neurogenic Overactive Bladder: an Update

Fate of manganese associated with the inhalation of welding fumes: potential neurological effects.

Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females

Trends of Overactive Bladder and Pharmacologic Treatment Among U.S. Women

Comparison of different types of therapy for overactive bladder: A systematic review and network meta-analysis

Current Concepts in the Treatment of Genitourinary Tract Disorders in the Older Individual

Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome—A Systematic Review